Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$21.68 USD
-0.32 (-1.45%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $21.69 +0.01 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
DNLI 21.68 -0.32(-1.45%)
Will DNLI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNLI
Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?
Perrigo (PRGO) to Report Q2 Earnings: Here's What to Expect
Other News for DNLI
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Denali Therapeutics (DNLI) and Owens & Minor (OMI)
Oppenheimer Remains a Buy on Denali Therapeutics (DNLI)
Buy Rating Affirmed for Denali Therapeutics Amid Strategic Moves and Regulatory Advancements
Denali Therapeutics price target lowered by $4 at Wedbush, here's why
Morgan Stanley Sticks to Their Buy Rating for Denali Therapeutics (DNLI)